| |
| |
|
| Insider
Information: |
Jones David Scott |
| Relationship: |
|
| City: |
Watertown |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
44,916 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$19,875 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
44,916 |
|
|
| Total
Value |
$19,875 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
|
|
| Stock
price went down : |
|
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
EyePoint Pharmaceuticals Inc |
EYPT |
|
2024-02-09 |
44,916 |
2020-06-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-02-09 |
4 |
D |
$28.80 |
$105,293 |
D/D |
(3,656) |
44,916 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,967 |
48,572 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-02-02 |
4 |
S |
$28.49 |
$5,954 |
D/D |
(209) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-02-02 |
4 |
OE |
$11.47 |
$2,397 |
D/D |
209 |
38,171 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-26 |
4 |
S |
$25.27 |
$660,370 |
D/D |
(26,017) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-26 |
4 |
OE |
$3.26 |
$177,398 |
D/D |
26,017 |
63,979 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-25 |
4 |
OE |
$3.26 |
$4,848 |
D/D |
600 |
38,562 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-25 |
4 |
S |
$25.00 |
$15,000 |
D/D |
(600) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-24 |
4 |
S |
$25.01 |
$282,621 |
D/D |
(11,300) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-24 |
4 |
OE |
$3.26 |
$90,822 |
D/D |
11,300 |
49,262 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
S |
$25.00 |
$22,500 |
D/D |
(900) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-23 |
4 |
OE |
$3.26 |
$6,790 |
D/D |
900 |
38,862 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
S |
$22.24 |
$772,691 |
D/D |
(34,166) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-22 |
4 |
OE |
$10.13 |
$353,359 |
D/D |
34,166 |
72,128 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-06 |
4 |
D |
$20.40 |
$84,599 |
D/D |
(4,147) |
37,962 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2024-01-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,285 |
42,109 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2023-02-09 |
4 |
D |
$4.17 |
$12,327 |
D/D |
(2,956) |
25,133 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2023-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,967 |
28,089 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2022-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
16,729 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2022-02-28 |
4 |
D |
$9.95 |
$11,244 |
D/D |
(1,130) |
15,599 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2022-02-09 |
4 |
D |
$10.13 |
$14,921 |
D/D |
(1,473) |
12,624 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2022-02-09 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,966 |
14,097 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2021-02-28 |
4 |
D |
$10.81 |
$18,399 |
D/D |
(1,702) |
7,380 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2021-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,105 |
9,082 |
0 |
- |
|
| EYPT |
EyePoint Pharmaceuticals ... |
SVP & Chief Commercial Officer |
• – – |
2020-06-30 |
4 |
D |
$0.76 |
$10,643 |
D/D |
(14,060) |
26,990 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
